GlassScriptPhysician profile
Michael A Gates
NPI 1043235179
$1,349.03
in general payments reported to CMS, 2019-2025
20 companies · $156 in 2025
The $156 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $94.94 · 2023: $566 · 2024: $430 · 2025: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $290.99 | 2021-2025 | Lifevest |
| Heartflow, INC. | $206.81 | 2023-2025 | Ffrct |
| Abbott Laboratories | $123.83 | 2023-2024 | Cardiomems, Gallant |
| Astrazeneca Pharmaceuticals LP | $99.66 | 2023-2024 | Andexxa, Farxiga |
| Pfizer INC. | $89.72 | 2023-2025 | |
| Scpharmaceuticals INC. | $81.82 | 2024-2025 | |
| Novo Nordisk INC | $77.94 | 2022-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $64.57 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $59.55 | 2023-2025 | |
| Daiichi Sankyo INC. | $43.03 | 2024 | Injectafer |
| Ucb, INC. | $42.51 | 2023 | Nayzilam |
| Amgen INC. | $28.75 | 2023-2024 | Repatha |
| Cvrx, INC. | $24.60 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $18.24 | 2023 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $17.71 | 2024 | Opsumit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $16.95 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $16.50 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $15.93 | 2023 | |
| Boston Scientific Corporation | $15.03 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.89 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.